We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock

Delisted

PRVB was delisted on the 26th of April, 2023.

63 hedge funds and large institutions have $96.2M invested in Provention Bio, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 17 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 16

33% more call options, than puts

Call options by funds: $1.83M | Put options by funds: $1.38M

18% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 17

5% more funds holding

Funds holding: 6063 (+3)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

27% less capital invested

Capital invested by funds: $131M → $96.2M (-$34.9M)

Holders
63
Holders Change
+3
Holders Change %
+5%
% of All Funds
1.39%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
20
Reduced
17
Closed
16
Calls
$1.83M
Puts
$1.38M
Net Calls
+$453K
Net Calls Change
-$1.5M
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$27.7M +$1.16M +90,000 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$13M +$682K +52,920 +4%
JJIJ
3
Johnson & Johnson Innovation - JJDC
New Jersey
$10.3M
BlackRock
4
BlackRock
New York
$6.28M +$326K +25,299 +4%
Millennium Management
5
Millennium Management
New York
$5.33M +$6.99M +542,553 +1,454%
Invesco
6
Invesco
Georgia
$4.67M +$4.57M +354,523 +232%
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$3.3M +$2.04M +158,249 +79%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$2.67M +$473K +36,668 +14%
SCM
9
Segantii Capital Management
Hong Kong
$2.62M +$305K +23,700 +9%
OM
10
Opaleye Management
Massachusetts
$1.53M +$2.14M +166,000 New
EGI
11
EAM Global Investors
California
$1.31M +$1.83M +142,223 New
RHJA
12
Rice Hall James & Associates
California
$1.24M +$987K +76,584 +131%
EI
13
EAM Investors
California
$1.02M +$1.42M +110,544 New
Goldman Sachs
14
Goldman Sachs
New York
$959K +$1.34M +104,240 New
Truist Financial
15
Truist Financial
North Carolina
$773K +$412K +32,000 +62%
WAM
16
Wealthspire Advisors (Maryland)
Maryland
$736K +$129K +10,000 +14%
WANY
17
Wealthspire Advisors (New York)
New York
$736K +$1.03M +80,000 New
SPC
18
Sigma Planning Corp
Michigan
$707K -$45.2K -3,505 -4%
Macquarie Group
19
Macquarie Group
Australia
$706K +$86.7K +6,725 +10%
Renaissance Technologies
20
Renaissance Technologies
New York
$688K +$964K +74,796 New
Northern Trust
21
Northern Trust
Illinois
$655K +$52.8K +4,099 +6%
BAAM
22
Baker Avenue Asset Management
California
$641K -$277K -21,500 -24%
California Public Employees Retirement System
23
California Public Employees Retirement System
California
$635K +$303K +23,500 +52%
Jane Street
24
Jane Street
New York
$634K +$888K +68,902 New
Allianz Asset Management
25
Allianz Asset Management
Germany
$427K +$599K +46,439 New

PRVB Hedge Fund Activity: Q1 2020 in Review

63 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q1 2020, worth a combined $96.2M — down 27% from $131M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new PRVB positions and 16 closed out — a net gain of 6 holders — while 20 added to existing stakes and 17 trimmed.

The largest buyer was Millennium Management, adding an estimated $6.99M. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $1.46M.

  • 63 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q1 2020, up from 60 in Q4 2019.
  • Funds reported $96.2M of Provention Bio, Inc. Common Stock stock for Q1 2020, down 27% quarter-over-quarter.
  • 22 funds opened new Provention Bio, Inc. Common Stock positions in Q1 2020 and 16 closed out, a net change of +6 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q1 2020 was Millennium Management, an estimated $6.99M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q1 2020 was Qube Research & Technologies (QRT), an estimated $1.46M sold.

Based on aggregated 13F filings for Q1 2020.